New brain radiation combo aims to fight tumors and save memory

NCT ID NCT07481786

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 3 trial tests two ways to treat lung cancer that has spread to the brain. One group gets targeted radiation to each tumor plus a drug (bevacizumab) that starves tumors of blood. The other group gets whole-brain radiation that tries to avoid the memory centers. The study will see which approach better controls brain tumors and protects thinking skills. About 220 adults with lung adenocarcinoma and multiple brain metastases are being recruited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

bevacizumab (a drug that blocks blood vessel growth to tumors)

What this could lead to

If successful, this could offer a more targeted brain radiation approach that better controls tumors while preserving memory and thinking skills.

What could go wrong

This is an early-stage Phase 3 trial, so results are not yet known. The experimental group adds a drug (bevacizumab) that carries risks like bleeding or high blood pressure, and the benefit over standard whole-brain radiation is unproven.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma of Lung brain cancer lung adenocarcinoma metastatic malignant neoplasm in the brain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sun yat-sen University Cancer Center

    RECRUITING

    Guangzhou, Guangdong, 510060, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Chongqing Medical University

    RECRUITING

    Chongqing, Chongqing Municipality, 400016, China

    Contact Email: •••••@•••••

  • The First Affiliated Hospital of Guangzhou University of Chinese Medicine

    RECRUITING

    Guangzhou, Guangdong, 510405, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••